182.70EURMkt Cap: —P/E: 21.404d ago
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous sys…
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$375.50BUSDP/E 122.7
$341.92BUSDP/E 24.5
$348.81BUSDP/E 25.0
$279.13BUSDP/E 22.3
$274.07BUSDP/E 23.6
$240.45BUSDP/E 24.5
$231.49BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$139.84BUSDP/E 32.2
$138.11BUSDP/E 14.9
Key Statistics
Company
Market Cap—
Enterprise Value8.79B $
Revenue (TTM)—
Gross Profit-3.29M $
Net Income (TTM)106.97M $
Revenue/Share—
Last Price182.70 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryGB
SectorHealthcare
Industry—
ISINBE0003823409
Valuation
P/E (Trailing)21.40
P/E (Forward)—
PEG—
EV/EBITDA-2666.40
EV/Revenue—
P/S—
P/B4.09
EPS (TTM)8.54
EPS (Forward)—
52W Range
182.2062% of range183.00
52W High183.00 EUR
52W Low182.20 EUR
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE5.02%
ROA-0.10%
Growth
Revenue Growth—
Earnings Growth5.40%
Cash Flow & Leverage
Operating CF-3.30M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-54.24M $
Net Debt/EBITDA16.46
Balance Sheet
Debt/Equity—
Current Ratio141.92
Quick Ratio141.92
Book Value/Sh44.62 EUR
Cash/Share1.121 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate1.080 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.55M
Float20.71M
Insiders53.49%
Institutions8.72%
Technical
SMA 5078.21 (+133.6%)
SMA 20071.72 (+154.7%)
Beta0.39
S&P 52W Chg20.80%
Avg Vol (30d)8
Avg Vol (10d)466
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—